The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls - Food and Drug Law Institute (FDLI)
The FDLI article discusses potential regulatory shifts under the Trump administration that could affect dietary supplement labeling, NDI notifications, and enforcement. Small businesses should monitor for relaxed enforcement but prepare for possible mandatory product listing requirements.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline, but businesses should assess readiness within 90 days.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Potential changes in FDA enforcement priorities and possible new mandatory product listing requirements for dietary supplements.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
Review current labeling compliance, especially for NDI notifications and structure function claims, and prepare for potential mandatory product listing.
Deadline
No immediate deadline, but businesses should assess readiness within 90 days.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewswire
- After 4-year review, FDA shuts down attempt to regulate CBD as a supplement and asks Congress for help - AgencyIQ by POLITICO
- US FDA New Dietary Ingredient Notification Submissions in the Last 4 Years - CIRS Group
- FDA's 2016 New Dietary Ingredient Draft Guidance - Food and Drug Law Institute (FDLI)
- Texas Updates Food Labeling Law: 44 Ingredients Require Warning Labels - CIRS Group